Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant docetaxel + cisplatin + 5-fluorouracil for locally advanced or node-positive gastric cancer
ISRCTN43859589Phase 2Completed
- Sponsor
- Universitätsklinikum Greifswald
- Start
- Sep 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and fluorouracil in gastric adenocarcinoma and gastric cancer (GC), sponsored by Universitätsklinikum Greifswald. Primary endpoint: Rate of curative (R0) resection. Started Sep 2007; status: completed.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
gastric adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on ISRCTN43859589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN43859589.